Drugs and Devices

FDA approves antiplatelet drug for use during PCI

On June 22, the U.S. Food and Drug Administration (FDA) approved Kengreal (cangrelor), an I.V. antiplatelet drug, for use in adults undergoing undergoing percutaneous coronary intervention (PCI). Read more.

Related Articles:

Leave a Reply

You have to agree to the comment policy.